Acetazolamide at 10 microM inhibited the relative invasion rate of four renal carcinoma cell lines by 18-74% in vitro.
Does acetazolamide reduce the invasive capacity of renal carcinoma cell lines in vitro?
Acetazolamide reduces the invasiveness of renal cancer cells in vitro, suggesting a potential role for carbonic anhydrase inhibitors in targeting tumor invasion.
Effect estimate: 18-74% inhibition
Acidification of the extracellular milieu of malignant tumors is reported to increase the invasive behavior of cancer cells. In normal tissues, production of acid is catalyzed by carbonic anhydrases (CAs), some of which are known to be overexpressed in certain cancers. To investigate the functional role of CA activity in such cancer cells, we analyzed the effect of acetazolamide, a potent CA inhibitor, on the invasive capacity of four renal carcinoma cell lines (Caki-1, Caki-2, ACHN, and A-498). We found that 10 microM acetazolamide inhibited the relative invasion rate of these cell lines between 18-74%. The Caki-2 and ACHN cell lines displayed the highest responsiveness, and their responses clearly depended on the acetazolamide concentration in the culture medium. Immunocytochemical and Western blotting results identified the presence of CA isoenzyme II in the cytoplasm of all four cell lines and CA XII on the plasma membrane in three of four cell lines. Because acetazolamide alone reduced invasiveness of these cancer cells in vitro, we conclude that the CAs overexpressed in these renal cancer cells contribute to invasiveness, at least in vitro, and suggest that CA inhibitors may also reduce invasiveness in other tumors that overexpress one or more CAs.
Parkkila et al. (Fri,) conducted a other in Renal cancer. Acetazolamide was evaluated on Relative invasion rate (18-74% inhibition). Acetazolamide at 10 microM inhibited the relative invasion rate of four renal carcinoma cell lines by 18-74% in vitro.